8-K: Johnson & Johnson Reports Strong Q4 and Full-Year 2023 Results, Reaffirms 2024 Guidance

Johnson & Johnson announced a 7.3% increase in fourth-quarter sales and a 6.5% increase in full-year sales for 2023, driven by strong performance in both Innovative Medicine and MedTech segments.

Summary

• Johnson & Johnson reported a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, with operational growth of 7.2%.
• The company's fourth-quarter earnings per share (EPS) increased by 39.3% to $1.70, and adjusted EPS rose by 11.7% to $2.29.
• Full-year 2023 sales grew by 6.5% to $85.2 billion, with operational growth of 7.4%.
• Full-year EPS decreased by 15.3% to $5.20 due to a one-time charge, but adjusted EPS increased by 11.1% to $9.92.
• Excluding the impact of the COVID-19 vaccine, operational growth was 10.9% for the fourth quarter and 9.0% for the full year.
• The Innovative Medicine segment saw operational sales growth of 7.2% for the full year, excluding the COVID-19 vaccine, driven by key products like DARZALEX, ERLEADA, and STELARA.
• The MedTech segment experienced a 12.4% operational sales growth for the full year, with the acquisition of Abiomed contributing 4.7%.
• Johnson & Johnson has reaffirmed its 2024 guidance, projecting operational sales growth of 5.0% to 6.0% and adjusted operational EPS of $10.55 to $10.75.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales growth, increased earnings, and reaffirmed guidance. While there are some negative aspects, such as the decrease in full-year EPS and the decline in COVID-19 vaccine sales, the overall tone is optimistic and forward-looking.

Positives

• Strong sales growth in both the fourth quarter and full year, driven by both Innovative Medicine and MedTech segments.
• Significant increase in fourth-quarter earnings per share (EPS) and adjusted EPS.
• Solid operational growth, particularly when excluding the impact of the COVID-19 vaccine.
• The MedTech segment showed strong growth, boosted by the acquisition of Abiomed.
• The company reaffirmed its 2024 guidance, indicating confidence in future performance.
• Several regulatory approvals and submissions were announced, highlighting the company's innovation pipeline.
• The Innovative Medicine segment saw growth driven by key products like DARZALEX, ERLEADA, and STELARA.

Negatives

• Full-year EPS decreased by 15.3% due to a special one-time charge.
• The COVID-19 vaccine sales significantly declined, impacting overall sales figures.
• Some products like ZYTIGA and IMBRUVICA in Oncology and REMICADE in Immunology experienced sales declines.
• Currency fluctuations had a negative impact on international sales.

Risks

• The company faces risks related to economic factors, competition, and challenges in new product development.
• There are uncertainties regarding the commercial success of new and existing products.
• The company is exposed to risks related to patent expirations and litigation, including product liability claims.
• Changes in healthcare regulations and cost containment trends could impact the company's performance.
• The company's ability to realize the anticipated benefits from the separation of the Consumer Health business is a risk.
• The company is exposed to financial instability of international economies and legal systems and sovereign risk.

Future Outlook

Johnson & Johnson re-confirmed its 2024 guidance, projecting operational sales growth of 5.0% to 6.0% and adjusted operational EPS of $10.55 to $10.75, reflecting growth of 7.4% at the mid-point.

Management Comments

• Joaquin Duato, Chairman and Chief Executive Officer, stated that Johnson & Johnson's full-year 2023 results reflect the breadth and competitiveness of their business and their focus on delivering for patients.
• He also expressed confidence in the company's ability to lead the next wave of health innovation, entering 2024 from a position of strength.

Industry Context

The results reflect a strong performance in the healthcare sector, with Johnson & Johnson leveraging its diverse portfolio in pharmaceuticals and medical devices. The company's focus on innovation and strategic acquisitions, such as Abiomed, positions it well for future growth in a competitive market.

Comparison to Industry Standards

• Johnson & Johnson's 7.3% Q4 sales growth is solid compared to peers like Pfizer and Merck, which have seen more modest growth or even declines in some quarters due to patent expirations and other factors.
• The 12.4% operational growth in MedTech, boosted by the Abiomed acquisition, is particularly strong compared to companies like Medtronic, which have faced challenges in certain segments.
• The company's 2024 guidance of 5-6% operational sales growth is in line with or slightly above the industry average, indicating a positive outlook.
• The adjusted EPS growth of 11.1% for the full year is competitive, though some biotech companies may have seen higher growth due to specific drug approvals or market dynamics.
• Compared to companies like Abbott, which also have a diverse portfolio, JNJ's performance in both Innovative Medicine and MedTech shows a balanced approach to growth.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and reaffirmed guidance.
• Employees may benefit from the company's continued growth and success.
• Customers will continue to have access to innovative healthcare products and solutions.
• Suppliers and creditors will likely see continued business opportunities with the company.

Next Steps

• Johnson & Johnson will conduct a conference call with investors to discuss the earnings release.
• The company will continue to focus on its strategic priorities and innovation pipeline.
• The company will continue to integrate recent acquisitions and drive growth in key segments.

Key Dates

Keywords

Johnson & Johnson, JNJ, earnings, sales, Innovative Medicine, MedTech, EPS, operational growth, financial results, guidance, COVID-19 vaccine, regulatory approvals, acquisitions, DARZALEX, ERLEADA, STELARA, Abiomed